CD8A and cancer: PD-1 blockade in combination with IL-2 administration is an emerging approach in treating cancer patients (42, 43), in which IL-2 improves PD-1 blockade therapy through skewing the differentiation program of PD-1+TCF1+ stem-like CD8+ T cells away from T cell exhaustion, while instead toward effector T cells (44).